CareDx Inc’s shares reached a 52-week high of $49.77 on Tuesday, trading at $49.69, as the company reported better-than-expected second-quarter results for 2026. The stock has surged 283.22% over the past year, lifting its market capitalization to $2.57 billion.
The diagnostics firm posted adjusted earnings per share of $0.37, exceeding the analyst consensus of $0.23. Total revenue rose 52% year-over-year to $132 million, while testing revenue climbed 61% to $99.9 million. Both figures surpassed expectations, with revenue outpacing the anticipated $113.82 million.
CareDx also raised its full-year outlook, citing strong demand for its transplant-related testing services. H.C. Wainwright maintained a neutral rating on the stock with a $46 price target, while InvestingPro’s Fair Value analysis indicated the shares may be overvalued. The company’s Piotroski Score stands at 9, reflecting robust financial health, and its PEG ratio is 0.2, according to the report.
